Clinical trials: Alveolar Lung Disease
Pulmonary Alveolar Proteinosis
Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
The purpose of this study is twofold: to assess routine cat scan (CT) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where CT is the gold-standard imaging technique for density quantification), and…
- Trial name
- PAP (NCT02081092)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lung Cancer
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900172
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 180 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
General Anesthesia, Ventilator-Induced Lung Injuries
Prevention of Postoperative Respiratory Complications
Given the huge number of patients mechanically ventilated during general anaesthesia, optimizing alveolar recruitment by limiting pulmonary and systemic aggression is a key objective for further progress in perioperative patient…
- Conditions
- General Anesthesia, Ventilator-Induced Lung Injuries, Postoperative Respiratory Complications
- Trial name
- RAMAGE (NCT06899295)
- Testing
- Continuous measurement of esophageal pressure Peso (cmH2O), Measurement of impedance variation with each respiratory cycle (EIT), Z in ohm, Measurement of regional respiratory compliance (EIT), Ohm/cmH2O
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bronchopulmonary Dysplasia
Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants
Despite considerable obstetric and neonatal advances in the care of very low birth weight (VLBW) neonates, bronchopulmonary dysplasia (BPD) continues to occur among 20 to 40% of surviving infants, and new ways for combatting this…
- Trial name
- GENBPD (NCT00904774)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients, Chronic Obstructive Pulmonary Disease
Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients
The cardiovascular component associated with COPD plays a major role in prognosis of the disease, being responsible of 25% of the deaths.
- Conditions
- Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients, Chronic Obstructive Pulmonary Disease, Bronchodilator Agents, Salmeterol
- Trial name
- SALM1 (NCT01271556)
- Testing
- Salmeterol, saline infusion (0.9 per cent sodium chloride)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Milan
Lung Cancer
Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00346320
- Testing
- 3-dimensional conformal radiation therapy
- Where
- 19 sites in Canada
- Volunteers
- 80 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01344824
- Testing
- bevacizumab, carboplatin, erlotinib hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, Adenocarcinoma
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime)…
- Trial name
- NCT00430261
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Lung Cancer, Lymphoma
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00734890
- Testing
- bevacizumab, vandetanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Alveolar Proteinosis (PAP), MARS
Macrophages, GM-CSF and MARS Proteinosis
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis (PAP), but the pathophysiological mechanisms of the respiratory phenotype are not known.
- Conditions
- Pulmonary Alveolar Proteinosis (PAP), MARS, Genetic Mutation
- Trial name
- MacroMARS (NCT04811274)
- Testing
- Blood collection, Bronchoalveolar lavage fluid collection
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Parenchymal Lung Diseases
Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases
Diffuse parenchymal lung diseases (DPLD) include a variety of respiratory conditions that affect either the pulmonary interstitium or the alveolar space .
- Trial name
- Microsemio-PI (NCT02961335)
- Testing
- Bronchoscopy, Confocal microendoscopy, Biopsy sampling
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Rouen
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Background: Healthy people have white blood cells that protect them against bacteria, viruses, and fungi. However, some people have diseases which cause the body to make white blood cells that do not work properly.
- Trial name
- NCT01842386
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
ARDS, Human, Ventilation Therapy; Complications
Assessment of the Hemodynamic Effects of PEEP According to Alveolar Recruitment During the ARDS
The corner stone of the treatment of ARDS is mechanical ventilation with high levels of positive end-expiratory pressure, also called PEEP. A high level of PEEP is recommended and frequently used.
- Conditions
- ARDS, Human, Ventilation Therapy; Complications, Alveolar; Disorder
- Trial name
- NCT05524558
- Testing
- Pulmonary artery catheter, Esophagal pressure
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Bicetre Hospital
Lung Cancer
Evaluating the Pulmonary Nodule With Imaging and Biomarkers
The study aims to determine if there are defining EBUS and confocal endoscopy features as well as exhaled alveolar gas VOC that can discriminate malignant pulmonary nodules or masses from benign etiology, thereby obviating…
- Trial name
- NCT01739881
- Testing
- Olympus Ultrathin Bronchofibervideoscope (XP260F)
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National University Hospital, Singapore
Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly…
- Trial name
- NCT00004859
- Testing
- carboplatin, paclitaxel, thalidomide
- Where
- 236 sites in United States, South Africa
- Volunteers
- 589 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Alveolar Proteinosis(PAP)
The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro
Autoimmune pulmonary alveolar proteinosis (aPAP) is a respiratory disease characterized by massive deposition of pulmonary surfactant in the alveoli, involving a variety of immune cells and factor disorders.
- Trial name
- NCT05640687
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Lung Cancer
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00425646
- Testing
- bevacizumab, imatinib mesylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Pulmonary Alveolar Proteinosis
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
This observational study was designed as a prospective epidemiological screening study. Patients who have applied to the centers participating in the study and who have previously been clinically or pathologically diagnosed with…
- Trial name
- NCT05300360
- Testing
- adenosine deaminase test
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- TRPHARM